2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

National Cheng Kung University, SPARK Taiwan

Bcount Rapid Bacterial Counting Platform

Future Company Type

Diagnostics

Prestartup

Expecting startup year /2021

No. of team members /5

Stage

Startup

Presenter

Name /Tien-Chun Tsai

Title /Researcher

Email /tctsai1018@gmail.com

Telephone /(Work) +886-6-2757575 ext.31380-218

Fax /

Mobile /+886-981-667-050

About the Team

Bcount is a Taiwanese startup team specialized in developing in-vitro diagnosis (IVD) platform, enabling the rapid and accurate bacterial counting. Our missions always satisfy the unmet needs in various potential markets, involving biomedical diagnostics, food safety, and bio-economy. We are leveraging our scientific knowledge with the innovative power of our collaborators for advancing R&D capabilities. In addition, Bcount is a cross-field team over marketing, microfluidic science, regulation, clinical trials, and AI imaging technique in the backgrounds of team members.

Brief Description of main products or services

The asymptomatic carriers with group B streptococcus (GBS) in pregnancy (prevalence rate ~20%) will infect vertically neonates during the parturition, leading to neonatal encephalopathy, neurodevelopment impairment, sepsis, and even death. The clinical strategy is antenatal GBS screening culture (1~3 days) during the 35th~37th weeks of gestation. However, some severe risks remain in unknown status, such as the preterm birth prior to the 35th weak and the false-negative result in screening culture. The Bcount Rapid Bacterial Counter consists of GBS-specific aptamer kit, disposable microfluidic chip, desktop fluorescent reader, and automatic image-processing software. It provides a rapid screening (~10 h) for pregnant women before parturition in order to prevent newborns from GBS infection.

Contact Person

Name /Tien-Chun Tsai

Phone /(Work) +886-6-2757575 ext.31380-218

Email /tctsai1018@gmail.com